著者

向井 將 向井 千珈子 浅岡 一之

出版者

耳鼻咽喉科臨床学会

雑誌

耳鼻咽喉科臨床 (ISSN:00326313)

巻号頁・発行日

vol.84, no.12, pp.1753-1762, 1991-12-01 (Released:2011-11-04)

参考文献数

18

被引用文献数

1 1

---

We have treated 38 adults with ankyloglossia with deviation of the epiglottis and larynx.1) The patients had type III occlusion of Angle's and had irregular teeth in the upper jaw.2) The patients' chief complaints were shoulder stiffness, cold extremities, feeling of obstruction in the throat, insomnia, fatigue, snoring, irritated, dry skin, incorrect articulation and muscle cramps during physical activity, pregnancy and/or sleep.3) Correction of the ankyloglossia and deviation of the epiglottis and larynx resulted in great relief of their chief complaints as well as their respiratory function.4) In addition, patients said that they breathed more easily, could bite well, and that their joints could bend better. They also remarked that they were less angry.However there were no significant changes in their incorrect articulations.

著者

犬山 征夫 浅岡 一之 中島 康夫 甲能 直幸 小津 雷助 増野 精二 堀内 正敏

出版者

耳鼻咽喉科臨床学会

雑誌

耳鼻咽喉科臨床 (ISSN:00326313)

巻号頁・発行日

vol.72, no.12, pp.1613-1620, 1979-12-01 (Released:2011-11-04)

参考文献数

15

被引用文献数

1

---

We gave OK-432, a preparation made from a low virulent strain of streptococcus hemolyticus, to 68 patients with head and neck cancer by intramuscular injection and 2 patients were treated with local application. Anatomical site of the tumor in 70 cases was as follows; nose and paranasal sinus 22, nasopharynx 17, base of oral cavity and tongue 14, mesopharynx 8, larynx 6 and miscellaneous 3. We administered OK-432 mainly as an adjuvant immunotherapy after radical surgery or radiotherapy. The daily dose of OK-432 was 0.2KE, then the dose was gradually augmented and the maintenance dose was 3-5KE. The longest duration of OK-432 administration was 3 years and 6 months. We evaluated OK-432 from the point of view of the immunological parameters and the recurrence rate. Complement level (CH50) and tuberculin reactivity were measured as possible indices of the humoral and cell-mediated immune status. “The six stage classification after CH50 and tuberculin reaction” as suggested by Nishioka was employed and an analysis carried out.The results obtained were as follows:1. OK-432 had no tumor-reducing effects in advanced or recurrent cases.2. Immunological findings suggested that OK-432 had prophylactic effects against recurrence and metastasis.3. The recurrence rate of OK-432-treated group was almost the same as that in the control group, however, the recurrence rate of OK-432 and FT-207 treated groups was 26%, this rate being considerably lower than that in the control group. We concluded that adjuvant chemo-immunotherapy was more effective than adjuvant immunotherapy alone for prevention of recurrence and metastasis.